Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 4/2017

01-04-2017 | Systematic Review

Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults

Authors: Tom D. Wilsdon, Ivanka Hendrix, Tilenka R. J. Thynne, Arduino A. Mangoni

Published in: Drugs & Aging | Issue 4/2017

Login to get access

Abstract

Background

The use of proton pump inhibitors (PPIs) in older adults is high, often inappropriate, and may cause harm. Deprescribing is defined as the reduction, withdrawal, or discontinuation of inappropriate medication.

Objective

We conducted a systematic review to determine the effectiveness of interventions to deprescribe inappropriate PPIs in older adults.

Methods

We searched MEDLINE, PubMed, Embase, the Cochrane Library, ProQuest Dissertations and Theses Global, and Google from inception to January 2017 for randomized and non-randomized studies describing the outcomes of interventions to deprescribe inappropriate PPIs in older adults (mean or median age of ≥65 years). Where available, clinically relevant outcomes were also assessed.

Results

We included 21 articles in our review. Six studies demonstrated effective interventions, 11 were inconclusive, and four were ineffective. Effective interventions included a population-wide education and promotion strategy, academic detailing for general practitioners, and inpatient geriatrician-led deprescribing. Methodological issues limited the interpretation of several studies. Standardization in outcome reporting was lacking, and clinical outcome data were absent. A comparison of intervention effectiveness was not possible because of their heterogeneity, which precluded a meta-analysis.

Conclusion

The limited available evidence suggests that some strategies are more successful than others in effectively deprescribing inappropriate PPIs in older adults. However, whether PPI deprescribing translates into better clinical outcomes remains unclear.
Appendix
Available only for authorised users
Literature
1.
Fox RK, Muniraj T. Pharmacologic therapies in gastrointestinal diseases. Med Clin N Am. 2016;100:827–50.CrossRefPubMed
2.
Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol. 1995;7:661–5.PubMed
3.
Chan WH, Khin LW, Chung YFA, Goh YC, Ong HS, Wong WK. Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding. Br J Surg. 2011;98:640–4.CrossRefPubMed
4.
Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;(5):CD002095.
5.
Swarbrick ET, Gough AL, Foster CS, Christian J, Garrett AD, Langworthy CH. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. Eur J Gastroenterol Hepatol. 1996;8:431–8.PubMed
6.
PBS Information Management Section Pharmaceutical Policy Branch. Expenditure and prescriptions twelve months to 30 June 2014. Canberra: Australian Government; 2014.
7.
PBS Information Management Section Pharmaceutical Policy Branch. Expenditure and prescriptions twelve months to 30 June 2015. Canberra: Australian Government; 2015.
8.
Othman F, Card TR, Crooks CJ. Proton pump inhibitor prescribing patterns in the UK: a primary care database study. Pharmacoepidemiol Drug Saf. 2016;25:1079–87.CrossRefPubMed
9.
Pottegard A, Broe A, Hallas J, de Muckadell OBS, Lassen AT, Lodrup AB. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Therap Adv Gastroenterol. 2016;9:671–8.CrossRefPubMedPubMedCentral
10.
Wallerstedt SM, Fastbom J, Linke J, Vitols S. Long-term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection-a cross-sectional population-based study. Pharmacoepidemiol Drug Saf. 2016;6:188–91.
11.
Gastrointestinal (version 6). eTG Complet [internet]. Melbourne: Therapeutic Guidelines Limited; 2016.
12.
Boghossian TA, Rashid Farah J, Welch V, Rojas-Fernandez C, Moayyedi P, Pottie K, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults (Protocol). Cochrane Database Syst Rev. 2015;(11):CD011969. doi:10.​1002/​14651858.​CD011969.
13.
Gastroenterological Society of Australia. Gastro-oesophageal reflux disease in adults. 5th ed. Mulgrave: Digestive Health Foundation; 2011.
14.
National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. London: NICE; 2014.
15.
Gadzhanova SV, Roughead EE, Mackson JM. Initiation and duration of proton pump inhibitors in the Australian veteran population. Intern Med J. 2012;42:e68–73.CrossRefPubMed
16.
Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther Adv Gastroenterol. 2012;5:219–32.CrossRef
17.
Ahrens D, Chenot J-F, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66:1265–71.CrossRefPubMedPubMedCentral
18.
Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4:e006544.CrossRefPubMedPubMedCentral
19.
Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176:172–4.CrossRefPubMed
20.
Masclee GMC, Sturkenboom MCJM, Kuipers EJ. A benefit-risk assessment of the use of proton pump inhibitors in the elderly. Drugs Aging. 2014;31:263–82.CrossRefPubMed
21.
Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–6.CrossRefPubMed
22.
Alhawassi T, Bajorek B, Krass I, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;9:2079–86.PubMedPubMedCentral
23.
Maggio M, Corsonello A, Ceda G, Cattabiani C, Lauretani F, Butto V, et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. J Am Med Assoc Intern Med. 2013;173:518–23.
24.
Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J. 2009;180:713–8.CrossRef
25.
Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909–17.CrossRefPubMed
26.
Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton pump inhibitors accelerate endothelial senescence. Circ Res. 2016;118:e36–42.CrossRefPubMed
27.
Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80:1254–68.CrossRefPubMedPubMedCentral
28.
Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract. 2014;31:625–30.CrossRefPubMed
29.
Lødrup AB, Reimer C, Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol. 2013;48:515–22.CrossRefPubMed
30.
Farrell B, Tsang C, Raman-Wilms L, Irving H, Conklin J, Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process. PLoS One. 2015;10:e0122246.CrossRefPubMedPubMedCentral
31.
Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30:793–807.CrossRefPubMed
32.
Higgins JP, Altman DG, Sterne JA, editors. Chapter 8: assessing risk of bias in included studies. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011.
33.
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–84.CrossRefPubMedPubMedCentral
34.
Atkins R, Smith L. Impact of pharmacy intervention on the use of proton-pump inhibitors in the hospital setting. Consult Pharm. 2013;28:786–92.CrossRefPubMed
35.
Batuwitage BT, Kingham JGC, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83:66–8.CrossRefPubMedPubMedCentral
36.
Hamzat H, Sun H, Ford JC, Macleod J, Soiza RL, Mangoni AA. Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. Drugs Aging. 2012;29:681–90.CrossRefPubMed
37.
Lampen-Smith A, Young J, O’Rourke MA, Balram A, Inns S. Blinded randomised controlled study of the effect of a discharge communication template on proton pump inhibitor prescribing. N Z Med J. 2012;125:30–6.PubMed
38.
Pratt NL, Kalisch Ellett LM, Sluggett JK, Gadzhanova SV, Ramsay EN, Kerr M, et al. Use of proton pump inhibitors among older Australians: national quality improvement programmes have led to sustained practice change. Int J Qual Health Care. 2016. doi:10.​1093/​intqhc/​mzw138.
39.
Reeve E, Andrews JM, Wiese MD, Hendrix I, Roberts MS, Shakib S. Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors. Ann Pharmacother. 2015;49:29–38.CrossRefPubMed
40.
Roughead EE, Kalisch Ellett LM, Ramsay EN, Pratt NL, Barratt JD, LeBlanc VT, et al. Bridging evidence-practice gaps: improving use of medicines in elderly Australian veterans. BMC Health Serv Res. 2013;13:514.CrossRefPubMedPubMedCentral
41.
Brulhart MI, Wermeille JP. Multidisciplinary medication review: evaluation of a pharmaceutical care model for nursing homes. Int J Clin Pharm. 2011;33:549–57.CrossRefPubMed
42.
Clyne B, Smith SM, Hughes CM, Boland F, Bradley MC, Cooper JA, et al. Effectiveness of a multifaceted intervention for potentially inappropriate prescribing in older patients in primary care: a cluster-randomized controlled trial (OPTI-SCRIPT Study). Ann Fam Med. 2015;13:545–53.CrossRefPubMedPubMedCentral
43.
Clyne B, Smith SM, Hughes CM, Boland F, Cooper JA, Fahey T, et al. Sustained effectiveness of a multifaceted intervention to reduce potentially inappropriate prescribing in older patients in primary care (OPTI-SCRIPT study). Implement Sci. 2016;11:79.CrossRefPubMedPubMedCentral
44.
Frely A, Chazard E, Pansu A, Beuscart JB, Puisieux F. Impact of acute geriatric care in elderly patients according to the Screening Tool of Older Persons’ Prescriptions/Screening Tool to Alert doctors to Right Treatment criteria in northern France. Geriatr Gerontol Int. 2016;16:272–8.CrossRefPubMed
45.
Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170:1648–54.CrossRefPubMed
46.
Khunti K, Kinsella B. Effect of systematic review of medication by general practitioner on drug consumption among nursing-home residents. Age Ageing. 2000;29:451–3.CrossRefPubMed
47.
Lang PO, Vogt-Ferrier N, Hasso Y, Le Saint L, Drame M, Zekry D, et al. Interdisciplinary geriatric and psychiatric care reduces potentially inappropriate prescribing in the hospital: interventional study in 150 acutely ill elderly patients with mental and somatic comorbid conditions. J Am Med Dir Assoc. 2012;13:406.e1–7.
48.
Michalek C, Wehling M, Schlitzer J, Frohnhofen H. Effects of ‘Fit fOR The Aged’ (FORTA) on pharmacotherapy and clinical endpoints–a pilot randomized controlled study. Eur J Clin Pharmacol. 2014;70:1261–7.CrossRefPubMed
49.
Mudge A, Radnedge K, Kasper K, Mullins R, Rofail S, Adsett J, et al. Effects of a pilot multidisciplinary clinic for frequent attending elderly patients on deprescribing. Aust Health Rev. 2016;40:86–91.CrossRefPubMed
50.
Mulvogue K, Roberts JA, Coombes I, Cottrell N, Kanagarajah S, Smith A. The effect of pharmacists on ward rounds measured by the STOPP/START tool in a specialized geriatric unit. J Clin Pharm Ther. 2016. doi:10.​1111/​jcpt.​12489.
51.
52.
Teichert M, Luijben SN, Wereldsma A, Schalk T, Janssen J, Wensing M, et al. Implementation of medication reviews in community pharmacies and their effect on potentially inappropriate drug use in elderly patients. Int J Clin Pharm. 2013;35:719–26.CrossRefPubMed
53.
Urfer M, Elzi L, Dell-Kuster S, Bassetti S. Intervention to improve appropriate prescribing and reduce polypharmacy in elderly patients admitted to an internal medicine unit. PLoS One. 2016;11:e0166359.CrossRefPubMedPubMedCentral
54.
Wehling M, Burkhardt H, Kuhn-Thiel A, Pazan F, Throm C, Weiss C, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing. 2016;45:262–7.CrossRefPubMed
Metadata
Title
Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults
Authors
Tom D. Wilsdon
Ivanka Hendrix
Tilenka R. J. Thynne
Arduino A. Mangoni
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 4/2017
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-017-0442-1

Other articles of this Issue 4/2017

Drugs & Aging 4/2017 Go to the issue

Original Research Article

Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer’s Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona

Original Research Article

Health Service Use, Costs, and Adverse Events Associated with Potentially Inappropriate Medication in Old Age in Germany: Retrospective Matched Cohort Study

Therapy in Practice

Pharmacological Management of People Living with End-Stage Chronic Obstructive Pulmonary Disease

Original Research Article

Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study

Review Article

Complementary and Alternative Medicine Use in Rheumatoid Arthritis: Considerations for the Pharmacological Management of Elderly Patients

Current Opinion

Selecting Potential Pharmacological Interventions in Sarcopenia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits